GEHC
GE HealthCare Technologies Inc.Evidence as of 2026-10-13The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on GEHC
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and…
Management team
- Mr. Roland Rott · CEO of UltrasoundFind on LinkedIn
- Mr. Kevin M. O'Neill · Chief Executive Officer of Pharmaceutical DiagnosticsFind on LinkedIn
- Dr. Taha Kass-Hout M.D., M.S. · Chief Science & Technology OfficerFind on LinkedIn
- Mr. Jan Makela · Chief Executive Officer of ImagingFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.4 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
What the evidence shows
The desk’s balance is Cautious ( -0.4 of a possible +2; was -0.4 before debate) with high confidence. Revenue across the recent quarters ranged from $ 4,777,000,000 in the quarter ended 2025-03-31 (Q1 2025) to $ 5,143,000,000 in the quarter ended 2025-09-30 (Q3 2025), with $ 5,131,000,000 reported in the quarter ended 2026-03-31 (Q1 2026, fiscal quarter ended 2026-04-22). Gross profit in the most recent reported quarters was roughly steady near $ 1,977,000,000–$ 1,990,000,000, operating income slipped from $ 654,000,000 (Q2 2025) to $ 515,000,000 (Q1 2026), and net income and diluted EPS trended lower each quarter to $ 389,000,000 and $ 0.85, respectively, in the quarter ended 2026-03-31. Cash declined from $ 4,492,000,000 as of 2025-12-31 to $ 2,261,000,000 as of 2026-03-31, long-term debt stayed around $ 10.0–10.3 billion, and shares outstanding fell modestly to 454,891,786 as of 2026-04-22; the valuation snapshot shows trailing P/E of 16.44 and price-to‑FCF of 38.27 on the stated price of $ 67.74.
What the debate changed
The desk did not drop any surviving claims; nearly everything raised survived the debate. Analysts pushed back chiefly over market-momentum and a single insider filing: the three‑month momentum figure (+ 9.9%) was treated as a weaker signal in the debate relative to the negative six‑ and twelve‑month momentum figures ( -8.2% and -15.8%), and one CFO Form 4 showing large share counts at zero reported value was flagged and weakened as an acquisition claim (action code A) in the packet. Those adjustments left the overall read intact — the evidence balance remained Cautious and the core financials, cash/debt profile, and filings-based risks continued to drive the conclusion.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenue was $4,777,000,000 in the quarter ended 31 March 2025 (fiscal Q1 2026, 2025-01-01 to 2025-03-31), $5,007,000,000 in the quarter ended 30 June 2025 (fiscal Q2 2025), $5,143,000,000 in the quarter ended 30 September 2025 (fiscal Q3 2025), and $5,131,000,000 in the quarter ended 31 March 2026 (fiscal Q1 2026, 2026-01-01 to 2026-03-31).
XBRL companyfacts · 0001932393-26-000031Gross profit was $1,985,000,000 in the quarter ended 30 June 2025 (fiscal Q2 2025), $1,990,000,000 in the quarter ended 30 September 2025 (fiscal Q3 2025), and $1,977,000,000 in the quarter ended 31 March 2026 (fiscal Q1 2026, 2026-01-01 to 2026-03-31).
XBRL companyfacts · 0001932393-25-000049Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
In the Annual Report on Form 10-K filed 4 February 2026, the company disclosed $10,003 million of borrowings outstanding as of December 31, 2025.
Item 1A risk-factor diff · 0001932393-26-000007 vs 0001932393-25-000005The 10-K filed 4 February 2026 added risk disclosures emphasizing significant investments in R&D with a focus on AI, cloud, edge computing, and software offerings and stated that the company "cannot guarantee that these investments will generate new offerings, attract customers, or generate sufficient revenue."
Item 1A risk-factor diff · 0001932393-26-000007 vs 0001932393-25-000005Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Three-month momentum is +9.9% while six-month momentum is -8.2% and the 12-month (12_1) momentum is -15.8% (percentiles: rank_momentum_6m = 27th percentile of 881; rank_momentum_12_1 = 19th percentile of 881).
Moneyta signal set · 2026-10-12weakened in debateShorter-term realized volatility is elevated: vol_30d_annualized = +23.1% and vol_90d_annualized = +35.6%, with vol_vs_own_history at the 74th percentile of 881.
Moneyta signal set · 2026-10-12Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F-reported holdings total "$25.00B" as of 2026-06-30.
13F holdings · 1233 filers · as of 2026-06-30Reported institutional holdings value declined by "-9.9%" quarter-over-quarter and the reported holder count fell by "-44" during the same period, with "181" exited positions in the quarter ended 2026-06-30.
13F holdings · 1233 filers · as of 2026-06-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Two recent headlines describe GE HealthCare as shifting toward pharmaceutical diagnostics and presenting itself as an AI-led, higher-margin medtech company.
News · insidermonkey.com · 2026-10-09A substantially similar headline about GE HealthCare's strategic shift and revenue visibility appeared on a second outlet, indicating the theme is being carried by multiple distinct outlets.
News · finance.yahoo.com · 2026-10-09Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Peter J. Arduini (President and CEO) reported purchases on 2026-09-01 totaling "$390k" for "5472" shares (Form 4 filings show action code F and trading_plan null).
Form 4 · Arduini Peter J (President and CEO) · $430k code F · 2026-09-01Peter J. Arduini (President and CEO) reported additional purchases on 2026-09-03 totaling "$445k" for "6303" shares (Form 4 filing shows action code F and trading_plan null).
Form 4 · Arduini Peter J (President and CEO) · $445k code F · 2026-09-03Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Using the provided discount and terminal assumptions, the price implies a free cash flow (FCF) growth rate of 25.59% (0.2559).
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month FCF is $809,000,000 and the price-to-FCF multiple is 38.27 (price $67.74; FCF per share $1.7702).
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
SEC-filed quarterly figures show stable-to-rising top-line revenue across the reported quarters and broadly steady gross profit, which are strong, contemporaneous accounting metrics (fundamentals-0 and fundamentals-1). Share-count reduction and explicit repurchases reported in filings provide concrete capital-return actions that can offset per-share metric pressure from lower operating and net income (fundamentals-5 and fundamentals-6). Multiple Form 4 insider purchases clustered in early September 2026 and material institutional ownership (13F-reported $25B) are verifiable signals from market participants and officers that support a favorable read when combined with news of strategic repositioning toward AI-led, higher-margin diagnostics and a product deployment in ASEAN (insider-0 through insider-4, ownership-0 and ownership-2, news-0, news-1, news-4). Lower beta and low correlation versus the broad market are observable market characteristics that reduce sensitivity to SPY-driven drawdowns (market-2), and trailing P/E calculated from reported TTM earnings is moderate at 16.44 (valuation-2). The revenue/gross-profit trends, share-reduction actions, insider buys, and strategic-shift headlines are from primary filings and multiple news sources, so the combined evidence strength is moderate-to-strong for a constructive interpretation.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.31
41 surviving claims rest on 21 distinct sources; the heaviest analyst carries 22% of them, and 98% of what the desk raised survived the debate.
The read rests on a moderate breadth of sources but a sizable share of surviving claims trace back to a single analyst’s contributions, and the desk’s very high internal survival rate suggests limited overturns during review. In practice that combination means the set is informative but somewhat fragile: it carries useful signals from official filings and market data, yet it would be sensitive to new, contrary primary filings or a material market-price move.
Peer context · computed, not argued
12-1 momentum ranks 2nd of 2 in Health Information Services (as of 2026-10-12).
6-month relative strength ranks 2nd of 2 in Health Information Services (as of 2026-10-12).
90-day volatility ranks 2nd of 2 in Health Information Services (as of 2026-10-12).
dividend yield ranks 1st of 2 in Health Information Services (as of 2026-10-12).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
10 filings· 3 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer−0.2 to the score
13 documents· 1 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.8 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.5 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.2 to the score
6 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
15 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+0.9 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on GEHC Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.